Felycin®-CA1 (Sirolimus Delayed-Release Tablets) is the First and Only Drug FDA Approved for the Management of Ventricular Hypertrophy in Cats with Subclinical Hypertrophic Cardiomyopathy (HCM), A Condition Affecting as Many as One in Seven Cats

Contributed by: Business Wire

Logo

Tags

Veterinary

FDA

Pets

Clinical Trials

Cardiology

Biotechnology

Health

Consumer

Pharmaceutical

PBI-Gordon Companies, Inc.

More Like This

PBI-Gordon Companies, Inc. Calls on Petspan to Cease and Desist False and Misleading Advertisement, Promotion and Sale of Compounded Rapamycin (Sirolimus) for HCM in Cats

PR Newswire associated0

Boehringer Ingelheim launches VETMEDIN® Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs

Pharmanovia Signs Novel Biologic In-Licensing Agreement With Lindis Biotech to Commercialise Catumaxomab for Treatment of Rare Condition, Malignant Ascites

PR Newswire associated0

Cresilon Announces International Distribution Agreement for VETIGEL with Covetrus

Capivasertib approved to treat patients with advanced breast cancer

Calliditas Therapeutics Presents Data at the 61st European Renal Association Congress

World's First Patent Acquired for Animal Supplement "Pinfenon" (S) (R)

Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function